[Effect of 6-keto prostaglandin E1 on the ascitic hepatoma-130 in vivo. Comparison with chemotherapeutic agent].

Abstract

The effect of 6-keto-prostaglandin E1 which has a potential action for antiplatelet aggregation was investigated against AH-130 in vivo in comparison with mitomycin C. The experimental schemes were as follows: Group I: Control, Group II: Thromboxane B2 (0.5 mg/kg, X 8, iv), Group III: 6-keto-PG-E1 (0.5 mg/kg, X 10, iv), Group IV: MMC (1.5 mg/kg, X 1, ip), Group V: 6-keto-PGE1 + MMC (0.5 mg/kg, X 10, iv, + 1.5 mg/kg, X 1, ip). The mean survival days, median survival day, and ILS% for 60 days disclosed an inhibitory effect of 6-keto-PGE1, 6-keto-PGE1 + MMC on AH-130 tumor cell growth. By contrast, TXB2, had a promoting effect on AH-130 tumor cell growth. It is concluded that 6-keto-PGE1 which has a structure activity relationship with antitumor agents, such as MMC, Diketocoriolin B, etc., played an important inhibitory role in tumor cell growth in AH-130 in vivo, particularly in combination with the antitumor agents, MMC.

• Authors: K Hiroshi, O Masanori, A Kaoru, Y Gompachi, S Hiroshi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 11 Issue 8 Pg. 1598-604 (Aug 1984) ISSN: 0385-0684 [Print] Japan
• PMID: 6089667 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Mitomycins
• Prostaglandins E
• Mitomycin
• 6-ketoprostaglandin E1
• Alprostadil

Topics

• Alprostadil (analogs & derivatives)
• Animals
• Cell Survival (drug effects)
• Drug Therapy, Combination
• Female
• Inclusion Bodies (ultrastructure)
• Liver Neoplasms, Experimental (drug therapy, pathology)
• Lysosomes (ultrastructure)
• Mitomycin
• Mitomycins (administration & dosage, therapeutic use)
• Prostaglandins E (administration & dosage, therapeutic use)
• Rats
• Rats, Inbred Strains
• Structure-Activity Relationship